Proniosomes are dry detailing of water-solvent bearer particles that are covered with surfactant and can be apportioned as required and dried out to frame niosomal scattering promptly before use on brief disturbance in hot fluid media inside of minutes. They have potential applications in the conveyance of hydrophobic and hydrophilic medications. Diverse clusters of proniosomes of Ketorolac tromethamine were readied by coacervation stage detachment strategy with distinctive proportions of polymers and surfactants. The physicochemical similarity of the medication and the polymers was considered by FTIR and DSC. The outcomes acquired demonstrated no physical-compound incongruently between the medication and the polymers. The readied frameworks were portrayed for embodiment effectiveness, shape, size and in vitro medication discharge. Release study was completed to research the draining of medication from the proniosomal framework amid capacity. On the premise of results acquired the gel KP 4 was upgraded and further utilized for the creation of transdermal patches with a backing layer (4% PVA) and a suitable rate controlling film. Distinctive rate controlling layers were readied with Eudragit RS-100 (ERS), Eudragit RL-100 (ERL) by mercury substrate method. The formulations were created and subjected to different physicochemical assessments and in vitro study. The patch manufactured with ERS (KTP 1) as rate controlling film was advanced as the best fix and further assessed for in vivo pervasion in rats. Investigation was completed to guarantee the connection between the in vitro and in vivo discharge design. The study exhibited that proniosomal transdermal patch in view of the ERS layer controlled discharge framework has the potential to deliver ketorolac tromethamine.
.
Determination of solubility of Ketorolac
Excess drug (50 mg) was added to 15 ml of each fluid taken in a 25 ml stoppered conical flask, and the mixtures were shaken for 24 h at room temperature (28±1 o C) on Rotary Flask Shaker. After 24 h of shaking, 2 ml aliquots were withdrawn at 2 h interval and filtered immediately using a 0.45 μ disk filter. The filtered samples were diluted suitably and assayed for Ketorolac by measuring absorbance at 322 nm. Shaking was continued until two consecutive estimations are the same. The solubility experiments were replicated for four times each (n=4).
Determination of Partition coefficient
30 ml of water and 30 ml of n-octanol solution was taken in the separating funnel. 100 mg of Ketorolac was added and shaken for 1 h. 1 ml of aqueous layer was removed and transferred into a 100 ml standard flask and made up to the mark with water. The absorbance was measured at 322 nm by using water as the blank 13 .
Drug lipid compatibility studies
Prior to formulation, to study the physical and chemical compatibilities of the drug with the lipids (Cholesterol and Lecithin) the following studies were conducted on the drug and lipid in the ratio 1:1. The physical mixtures were stored for 7 days at 50 °C before study. FTIR spectra of the mixture of drug and lipid were compared with the spectra of individual components 14, 15 .
The DSC thermogram of the physical mixture of drug and lipid (1:1 ratio) was obtained and compared with that of pure drug. 5 mg Samples were accurately weighed, sealed in an aluminium pan of 40 µL capacity and equilibrated at 25 °C, subjected to the DSC run over the temperature range of 25 to 200°C at the heating rate of 5 °C/min.
Formulation development of Ketorolac proniosomes
Proniosomes were prepared using coacervation phase separation method 14, 16, 17 . Using a wide-mouth glass tube, 100 mg of Ketorolac with surfactant (span 60 or tween 80), lecithin, and cholesterol were mixed with 2.5 ml of absolute ethanol. The open end of the glass tube was covered with a lid and the tube was warmed in a water bath at 65± 8 o C for 5 min. 1.6 ml of PBS was added, and the mixture was further warmed in the water bath for about 2 min so that a clear solution was obtained. The mixture was allowed to cool to room temperature until the dispersion was converted to proniosomal gel. Table 1 explains the formulation of Ketorolac proniosomes.
Evaluation of Proniosomes

Measurement of Proniosomal gel pH and viscosity
The pH of the gel was measured using pH meter before and after incorporation of the drug. Viscosity of the gel was determined using a
Brook field viscometerC for 30 min. The supernatant was recovered and assayed spectrophotometrically at 322 nm 14 .
The percentage of drug encapsulation (EP (%)) was calculated by the following equation:
Where C t is the concentration of total Ketorolac C r is the concentration of free Ketorolac The proniosomal gel (100 mg) was hydrated with PBS (10 ml) in a small test tube by manual shaking for 5 min and the resulting niosomes were observed under an optical microscope at 100 X magnification. The average size of 100 vesicles was measured using calibrated ocular and stage micrometer in the microscope.
In vitro release study
In vitro diffusion study of proniosomal gel was performed in Franz diffusion cell that has a receptor compartment with an effective volume, approximately 25 ml and an effective surface area of permeation of 3.14 sq cms 10, 16 . 
Stability studies
The stability studies were conducted according to ICH guidelines [18] [19] [20] .
The stability of vesicles to retain the drug was assessed by keeping 
Optimization of prepared proniosomes
Optimization of proniosomes was done based on the evaluated parameters such as particle size, %EE, drug release profile and stability study. One of the criteria in optimizing proniosome was a drug release, i.e., the proniosomes with high cumulative drug release will be selected as the best batch. 4 gm of Poly vinyl alcohol was dissolved in 100 ml water, and the solution was poured on to the mercury surface and dried at 60°C for 6 h.
Rate Controlling Membrane
ERL and ERS rate controlling membranes were prepared by dissolving 300 mg of respective polymers in 5 ml solvent (Chloroform). Di-n-Butyl phthalate (30% w/w of polymer) was used as the plasticizer to optimize the best rate controlling membrane with flexibility, elegance, uniformity, etc. 
Fabrication of Proniosome drug reservoir
2×3 cm backing membrane was cut out; three edges of the backing layer were then sealed with the edges of rate controlling membrane using adhesive tape. The weighed quantity (1 g) of gel was transferred into the reservoir patch. After filling, the unsealed edge was sealed using adhesive tape. The obtained reservoir patch was then pasted to an adhesive plaster (The backing layer should face to the plaster). A release liner was placed over the adhesive coated rate controlling membrane.
Evaluation of patches
Percentage of moisture content
The films were weighed individually and stored in dessicator containing activated silica at room temperature for 24 h. Individual films were weighed repeatedly until they showed a constant weight.
The percentage of moisture content was calculated as the difference between initial and final weight with respect to final weight.
Percentage moisture uptake
The films were weighed accurately and placed in the desiccators containing 100 mL of saturated solution of potassium chloride, which maintains 80-90% RH. After 3 days, the films were taken out and weighed. The study was performed at room temperature. The percentage moisture absorption was calculated using the formula:
% moisture absorption = Final weight− Initial weight / Initial weight ×100
Mass Variation
The patches were subjected to mass variation by individually weighing 10 randomly selected patches. [23] [24] [25] [26] In vitro drug diffusion study was carried out by using Franz-diffusion cell. In this method pre hydrated cellophane was used as the model membrane. The membrane was placed between the donor compartment and the reservoir compartment (phosphate buffer pH7.4). The patch was placed on the membrane, and the compartments clamped together. The receptor compartment was filled with phosphate buffer pH 7.4 and hydrodynamics in the receptor compartment was maintained by stirring with a magnetic bead at 100 rpm. Samples were withdrawn and replaced with receptor medium and assayed spectrophotometrically at 322 nm and the amount of drugs released at various time intervals were calculated.
In vitro drug release study
Optimization of Ketorolac patches
Optimization of the best patch was done based on the drug release profile i.e, the patch with the highest cummulative drug release in 24 h in a controlled manner and also based on other evaluated parameters such as moisture absorption, moisture loss and mass variation. 7 In order to understand the mechanism of drug release, in vitro drug release data were treated to kinetic models such as zero order, first order, Higuchi model and Korsemeyerpeppa"s model.
Curve fitting analysis
Zero order kinetics
It describes the system where the drug release rate is independent of its concentration of the dissolved substance. A graph was plotted between time taken on x-axis and the cumulative percentage of drug release on y-axis, if the plot is linear then the data obeys zero-order kinetics. The equation for zero order release is Q t =Q 0 +K 0 t Q 0= initial amount of drug, Q t= cumulative amount of drug release at time "t", K 0= zero order release constant, t=time in hours.
First order Kinetics
A graph was plotted between the time taken on x-axis and the log cumulative percentage of drug remaining to be released on y-axis, if it yields a straight line, it indicates that the release follows first order 
Higuchi model
The Higuchi equation suggests that the drug release mechanism is diffusion. A graph was plotted between the square root of time taken on x-axis and cumulative percentage of drug release on y-axis. If it yields a straight line, indicates that the drug was released by diffusion mechanism. The slope is equal to "K". The Higuchi release equation is
Q= cumulative amount of drug release at time "t", K H= Higuchi constant, t=time in hours.
Korsemeyerpeppa's equation model
To the study the mechanism of drug release from the formulation, the released data were fitted to exponential equation which is often used to describe the drug release behavior from polymeric system.
F=fraction of drug released at time"t", M t =amount of drug released at time"t", M=total amount of drug in dosage form, K m =kinetic constant, n = diffusion exponent (related to mechanism of release) and t=time in hours.
A graph was plotted between the log time taken on x-axis and the log cumulative percentage of drug release on y-axis, yields a straight line with a slope equal to "n" and the "K" can be obtained from y intercept.
In vivo drug release study
To find out the systemic bioavailability of formulated transdermal patches, 6 Male Wistar rats were selected. Rats were fasted overnight. The dorsal surface of the rat was clean shaved, and the optimized transdermal patch was fixed. Blood samples (200 µl) were drawn by retro-orbital plexus puncture with the aid of the capillary tube at 1, 2, 4, 6, 8, 12, 16, 20 and 24 h. The samples were collected in heparinized eppendorff tubes containing 3.8% trisodium citrate (100 µl) which acts as a complexing agent and centrifuged at 5000 rpm for 6 min, and collected the plasma and stored at -20ᴼ C until analysis (Fig-1) .
Fig 1: Different stages of animal study (A-Shaved to remove the dorsal hair, 2-Adhered patch on dorsal skin, 3-Retro orbital blood collection)
The plasma samples were taken in a centrifuge tube containing equivalent quantity of 10M K 2 CO 3 , in order to precipitate the whole blood proteins, and centrifuged again at 5000 rpm for 6 min. 2 ml of ethyl acetate was added to the supernatant and centrifuged again at 5000 rpm for 5 min. The separated organic phase was transferred into clean glass tubes in order to evaporate from the organic solvent by keeping it inside a vacuum oven. After the organic phase was completely evaporated, about 300 µl of phosphate buffer pH 7.4 was added and centrifuged at 6000 rpm for 5 min. The supernatant solution was analyzed at 322 nm.
Institution Animal Ethics committee Approval Number: SDCP/IAEC-07/2011-12
Results and Discussions
Preformulation studies of ketorolac
Melting point determination
The melting point of unadulterated ketorolac tromethamine was resolved utilizing melting point contraption and was observed to be 163-167 0 C.
UV Spectroscopy
The λ max of ketorolac was determined by using UV spectrophotometer. The λ max was found out to be 322 nm, similar to the previous reported literature.
Determination of solubility of Ketorolac
Ketorolac was freely soluble in water & methanol, slightly soluble in tetrahydrofuran and insoluble in acetone & toluene.
Determination of partition coefficient
The partition coefficient was found to be 2.32
Drug-Excipient compatibility studies
Infrared spectra of Ketorolac as well as its proniosome showed characteristic peaks at 1699 cm exhibiting the endothermic peak at 161.39˚C.
Fig 2: A) FTIR spectrum of pure Ketorolac tromethamine B) Ketorolac+cholesterol
Evaluation of proniosomes
The formulations were studied for physical characteristics like colour and appearance, determination of viscosity and were found to be within the acceptable limits as indicated in table 2.
Colour and appearance
All the formulations had a yellowish brown to slight yellow colour and had semisolid consistency. The gel definitions displayed great spreadability and thickness.
Optical microscopy and vesicle size determination
The span of 100 particles was dictated by optical microscopy, and the particles uncovered unilamellar vesicles with no agglomeration or total. The mean particle size was in the range of 2.98 to 5.01 µm. has a much lower hydrophobicity than spans. It was observed that the gel formulation showed good spreadability, and viscosity.
Determination of encapsulation efficiency
The encapsulation efficiency of the formulated proniosomes were formulations after the one-month period. Thus, both Span 60 and
Tween 80 based proniosomes of ketorolac seemed to exhibit good stability at low temperatures. The entrapment efficiency of our proniosomes ranged between 80-90% compared to the 40-70%
reported by Mishra 29 for proniosomes of Naproxen. 
In vitro release study
The in vitro releases from ketorolac proniosomes were investigated by using Franz-diffusion cell. 
Stability studies
Physical stability of proniosomal formulations were studied for a period of one month. The EE were determined (table 4) 
Optimization of Proniosome Gel
KP 4 was optimized by considering particle size (2.98±0.45), % EE (93.53), % CDR (91.73) and stability. Therefore KP 4 was selected for fabricating transdermal patches.
Evaluation of transdermal patches of ketorolac
Two formulations of Ketorolac transdermal patches were formulated using KP 4 as optimized proniosome gel and ERL & ERS as rate controlling membranes. The prepared transdermal patches were transparent, smooth, and uniform.
Percentage moisture content
The percentage moisture content was found to be 5.13% and 6.96%
for KTP1 and KTP2 respectively. The lowest percentage moisture loss was found in patches fabricated with ERS as rate controlling membrane.
Fig 4: A) DSC of Ketorolac tromethamine; B) Formulation
Percentage moisture uptake
The percentage moisture uptake was found as 1.76% and 2.48% for KTP 1 and KTP 2 respectively. The lowest percentage moisture uptake was found in patches fabricated with ERS as rate controlling membrane.
Mass variation
The mass was found to be uniform in the prepared batches and varied from 0.063%±0.07 mg to 0.068%±0.09. Table 5 explains the % CDR of patches after 24 h. KPT1 was the best with 88% drug release compared to 82% of KPT2.
In vitro study
Optimization of best patch
Out of two formulations KTP 1(ERS as RC membrane) exhibited good mechanical properties and release pattern. Hence KTP 1 had been optimized as the best patch.
Curve fitting analysis
In this study, two formulations released variable amounts of ketorolac through semi permeable membrane in the in vitro fluid. To examine the drug permeation kinetics and mechanism, the data of KTP 1 were fitted to models representing zero-order, first-order, Higuchi and Korsemeyer-Peppas. The graphs are shown in figure 5 and 6. Male wistar rats. Blood samples were analyzed UV spectrophotometrically at 322 nm. Table 6 explains the % CDR of samples 1-6 after 24 h. The in vitro and in vivo correlation of formulation KTP1 after 24 h is shown in figure 7 .
The system shows 78.66% of drug release in in vivo method and then to determine the correlation between the in vitro data the release pattern analysis was carried out, which revealed that they were well related and followed zero order release in a biological system also.
Conclusions
Ketorolac ( 
